HTLV-II-associated neurological disease
What is HTLV-II-associated neurological disease?
HTLV-II-associated neurological disease is a rare condition that affects the nervous system. It happens when someone infected with the Human T-cell Lymphotropic Virus Type II develops nerve or brain problems. HTLV-II is a retrovirus that infects white blood cells and can spread through blood, sexual contact, or from mother to child during birth or breastfeeding.
Most people infected with HTLV-II never develop symptoms. Only a small percentage develop neurological complications. When the virus does affect the nervous system, it can cause inflammation in the spinal cord and brain. This inflammation damages nerve pathways that control movement, sensation, and other body functions.
The disease develops slowly over months or years. Early detection through blood testing can help identify the viral infection before serious nerve damage occurs. Understanding your HTLV-II status is important for protecting your health and preventing transmission to others.
Symptoms
Common symptoms of HTLV-II-associated neurological disease include:
- Muscle weakness in the legs that slowly gets worse over time
- Difficulty walking or maintaining balance
- Numbness or tingling in the legs and feet
- Bladder control problems or frequent urination
- Lower back pain that does not improve with rest
- Stiffness in the leg muscles or increased muscle tone
- Reduced sensation to touch or temperature in the lower body
- Sexual dysfunction or reduced sensation
Many people with HTLV-II infection remain asymptomatic for years or their entire lives. Neurological symptoms develop in only a small fraction of infected individuals. When symptoms do appear, they typically progress gradually rather than suddenly.
Concerned about HTLV-II-associated neurological disease? Check your levels.
Screen for 1,200+ health conditions
Causes and risk factors
HTLV-II-associated neurological disease is caused by chronic infection with the HTLV-II virus. The virus infects certain white blood cells and can remain dormant in the body for decades. Scientists believe the neurological damage happens when infected immune cells trigger inflammation in the spinal cord and brain tissue. This chronic inflammation gradually damages the protective coating around nerves and the nerve fibers themselves.
Risk factors include receiving contaminated blood transfusions before screening began in the 1980s, injection drug use with shared needles, and sexual contact with infected partners. Indigenous populations in North and South America have higher rates of HTLV-II infection. Having the virus does not guarantee you will develop neurological disease, but it increases the risk. Factors that may trigger disease development in infected people are not fully understood but may include genetics and immune system function.
How it's diagnosed
Diagnosis begins with blood tests that detect antibodies to HTLV-I and HTLV-II. Because these viruses are closely related, most screening tests check for both at the same time. If the antibody test is positive, specialized confirmatory testing helps determine which virus type is present. Your doctor may also order spinal fluid analysis to look for signs of inflammation and to detect viral genetic material in the nervous system.
Imaging tests like MRI scans can reveal inflammation or damage in the spinal cord and brain. Neurological exams assess muscle strength, reflexes, sensation, and walking ability. Because HTLV-II neurological disease is rare and progresses slowly, diagnosis often takes time. Talk to a doctor about specialized testing options if you have risk factors or unexplained neurological symptoms. We are building tools to help you connect with doctors who can coordinate this testing.
Treatment options
Treatment approaches for HTLV-II-associated neurological disease include:
- Antiviral medications may be tried, though their effectiveness is not well established for HTLV-II
- Corticosteroids to reduce inflammation in the spinal cord and brain tissue
- Immunomodulating drugs to help control the immune response
- Physical therapy to maintain muscle strength and mobility
- Medications for bladder control problems and muscle stiffness
- Pain management through medications or nerve stimulation techniques
- Assistive devices like canes or walkers as needed for mobility
- Regular monitoring with neurological exams and imaging studies
No cure currently exists for HTLV-II infection or its neurological complications. Treatment focuses on managing symptoms, slowing disease progression, and maintaining quality of life. Early diagnosis allows for earlier intervention, which may help preserve function. Work with a neurologist or infectious disease specialist who has experience with HTLV-related conditions.
Frequently asked questions
HTLV-I and HTLV-II are closely related retroviruses that infect white blood cells. HTLV-I is more common and more often causes disease, including a specific type of leukemia and a progressive neurological condition. HTLV-II is less common and less likely to cause disease. When HTLV-II does cause neurological problems, the symptoms are similar to those caused by HTLV-I. Blood tests often detect both viruses together and require additional testing to determine which type is present.
This condition is very rare. Only a small percentage of people infected with HTLV-II ever develop neurological complications. HTLV-II infection itself is uncommon in most populations, though it is more prevalent among indigenous groups in the Americas and people who used injection drugs. Even among those with HTLV-II infection, most remain healthy throughout their lives. The exact incidence of neurological disease in HTLV-II carriers is not well established due to the rarity of both the infection and its complications.
No, HTLV-II cannot spread through casual contact like hugging, sharing utensils, or breathing the same air. The virus spreads through blood, sexual contact, and from mother to child during pregnancy, birth, or breastfeeding. It can also transmit through sharing needles or receiving contaminated blood products. Blood banks in developed countries screen for HTLV, making transmission through transfusions extremely rare today. Simple hygiene measures and safe practices prevent transmission to household members and others.
The time between infection and symptom development varies widely and can span decades. Many people remain infected for their entire lives without developing symptoms. When neurological disease does develop, it typically appears after 10 to 40 years of infection. Symptoms progress gradually over months to years rather than appearing suddenly. Regular monitoring of people known to have HTLV-II infection can help catch early signs of neurological involvement before significant disability occurs.
No vaccine currently exists to prevent HTLV-II infection. Prevention relies on avoiding exposure to infected blood and body fluids. This includes practicing safe sex, never sharing needles, and for infected mothers, considering alternatives to breastfeeding. Blood banks screen donations for HTLV to protect the blood supply. If you know you have HTLV-II infection, informing sexual partners and healthcare providers helps prevent transmission and ensures appropriate monitoring.
The prognosis varies depending on when the condition is diagnosed and how it responds to treatment. The disease typically progresses slowly, and some people maintain stable function for years with treatment. Others experience gradual decline in mobility and independence. Early diagnosis and treatment may slow progression and help maintain quality of life. Working closely with neurological specialists and following treatment recommendations provides the best chance for a favorable outcome.
Testing is recommended for sexual partners and people who may have shared needles with an infected person. Children born to mothers with HTLV-II should be tested because the virus can pass from mother to child. Other family members generally do not need testing unless they had blood contact or other high-risk exposure. A doctor can help assess individual risk and determine who should be tested. Knowing your status helps you take steps to protect your health and prevent transmission.
HTLV-II does not truly go dormant and reactivate like some other viruses. Instead, it remains present in the body at low levels throughout life once infection occurs. The virus integrates into the DNA of infected white blood cells and reproduces slowly. Neurological disease may develop after many years, but this represents ongoing viral presence rather than reactivation. The immune system keeps the virus under control in most people, which is why only a small percentage develop complications.
HTLV-II infects certain white blood cells but generally does not cause significant immune suppression in most people. This differs from HIV, which severely damages the immune system. Most people with HTLV-II maintain normal immune function and do not have increased infections. However, the presence of the virus does trigger an ongoing immune response. This chronic immune activation may contribute to inflammation in tissues like the nervous system in susceptible individuals.
Staying physically active through regular exercise helps maintain muscle strength and mobility. Physical therapy provides targeted exercises to address specific weakness patterns. A healthy diet rich in anti-inflammatory foods may support overall nervous system health. Avoiding alcohol and smoking protects nerve function. Managing stress through mindfulness or relaxation techniques can help with pain and quality of life. These lifestyle measures work best alongside medical treatment rather than replacing it.